Drug Trial Radar · NCT05688579
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
8,000
Planned (sponsor's estimate)
Start
Apr 16, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Nanfang LiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Elevated aldosterone causes moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. Aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently, the use of mineralocorticoid receptor antagonists(MRA) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. Therefore, the purpose of this clinical trial is to assess the effect of MRA on cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.
Conditions
- Hypertension
- Hyperaldosteronaemia
Interventions
Mineralocorticoid Receptor Antagonists(MRAs)Drug
Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
Blank controlOther
Participants will be treated with the original antihypertensive drugs for 48 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of the composite endpointTime frame: 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.